HNPPV联合舒利迭长期治疗稳定期重度COPD合并呼吸衰竭患者的疗效及安全性

摘要

Objective To evaluate the efficacy and safety of the combination treatment of home noninvasive positive pressure ventilation (HNPPV) and seretide in stable chronic obstructive pulmonary disease (COPD) patients. Methods Sixty patients with stable severe COPD after hospital discharge were divided into two groups: the HNPPV + serectide group (n = 30) and the control group with seretide alone (n = 30). Before and after one year follow-up observation, the following parameters were compared, including lung function test, arterial blood gases, 6-min walking distance, mean pulmonary arterial pressure, mortality and hospitalization rates. Results Various physiological indicators of the two groups on admission were similar (all P >0.05). After one year therapy, the mortalities of the two groups were not statistically significant different (P>0. 05). The physiological indicators in the HNPPV + seretide group were statistically improved, compared to the control group (P < 0.05 or <0. 01 ). Conclusions Combination treatment of home noninvasive positive ventilation and seretide in paients with stable severe COPD is more effective than that with seretide alone.%目的 探讨家庭无创正压机械通气(HNPPV)联合舒利迭长期治疗稳定期重度慢性阻塞性肺疾病(COPD)合并呼吸衰竭患者的疗效及安全性.方法 选择60例稳定期重度COPD合并呼吸衰竭患者,根据治疗方案不同分为HNPPV+舒利迭组(观察组)、单用舒利迭组(对照组)各30例.分别观察两组治疗前、治疗1年后肺功能、动脉血气分析、6 min行走距离、肺动脉平均压力、病死率及1年内住院次数等指标.结果 治疗前两组各生理学指标比较差异无统计学意义(P均＞0.05)；治疗1年后,观察组各生理学指标均优于对照组(P＜0.05或＜0.01).结论 HNPPV联合舒利迭治疗稳定期重度COPD合并呼吸衰竭患者安全、有效.